NOD2 Polyclonal Antibody, ALEXA FLUOR® 488 Conjugated

Applications

  • FCM

Reactivity

  • Human

Predicted Reactivity

  • Mouse
  • Rat
  • Dog
  • Cow
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-7084R-A488
Product Name NOD2 Polyclonal Antibody, ALEXA FLUOR® 488 Conjugated
Applications FCM
Reactivity Human
Predicted Reactivity Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit
Specifications
Conjugation ALEXA FLUOR® 488
Host Rabbit
Source KLH conjugated synthetic peptide derived from human CARD15
Immunogen Range 251-350/1040
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition Store at 4°C for 12 months.
Target
Gene ID 64127
Swiss Prot Q9HC29
Subcellular location Cytoplasm
Synonyms ACUG; Arthrocutaneouveal granulomatosis; BLAU; CARD15; Caspase recruitment domain protein 15; Caspase recruitment domain-containing protein 15; IBD1; Inflammatory bowel disease protein 1; LRR containing protein; LRR-containing protein; Nod2; NOD2 protein; NOD2_HUMAN; NOD2B; nucleotide binding oligomerization domain 2; nucleotide-binding oligomerization domain 2; Nucleotide-binding oligomerization domain-containing protein 2; PSORAS1.
Background Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) . EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.
Application Dilution
FCM 1:20-100